Evidence map›Paper›PMID 40177542›Full record

ArticleActa pharmaceutica Sinica. B2025

NIR-II-activated whole-cell vaccine with ultra-efficient semiconducting diradical oligomers for breast carcinoma growth and metastasis inhibition.

Yijian Gao, Yachao Zhang, Yujie Ma, Xiliang Li, Yu Wang, Huan Chen, Yingpeng Wan, Zhongming Huang, Weimin Liu, Pengfei Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Universal off-the-shelf TGF-Acta pharmaceutica Sinica. B · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yijian GaoCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Yachao ZhangKey Laboratory of Biomedical Imaging Science and System, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China.
Yujie MaCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Xiliang LiCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Yu WangCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Huan ChenCenter of Super-Diamond and Advanced Films (COSDAF), Department of Chemistry, City University of Hong Kong, Hong Kong SAR 999077, China.
Yingpeng WanCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Zhongming HuangCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.
Weimin LiuTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Pengfei WangTechnical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Lidai WangDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR, China.
Chun-Sing LeeCenter of Super-Diamond and Advanced Films (COSDAF), Department of Chemistry, City University of Hong Kong, Hong Kong SAR 999077, China.
Shengliang LiCollege of Pharmaceutical Sciences, the Fourth Affiliated Hospital of Soochow University, Suzhou Medical College, Soochow University, Suzhou 215123, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-performance phototheranostics with combined photothermal therapy and photoacoustic imaging have been considered promising approaches for efficient cancer diagnosis and treatment. However, developing phototheranostic materials with efficient photothermal conversion efficiency (PCE), especially over the second near-infrared window (NIR-II, 1000-1700 nm), remains challenging. Herein, we report an ultraefficient NIR-II-activated nanomedicine with phototheranostic and vaccination capability for highly efficient

Indexed as

Breast carcinomaImmunotherapyNanoparticlesNIR-IIPhotothermal therapySemiconducting oligomerTheranosticsVaccine

Identifiers

PMID40177542
PMCPMC11959919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.